Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) EBITDA Margin (2016 - 2025)

Guided Therapeutics' EBITDA Margin history spans 16 years, with the latest figure at 120.34% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 5327966.0% to 120.34% in Q4 2025 year-over-year; TTM through Dec 2025 was 309.26%, a 2981931.0% increase, with the full-year FY2025 number at 309.26%, up 2980503.0% from a year prior.
  • EBITDA Margin hit 120.34% in Q4 2025 for Guided Therapeutics, up from 808.33% in the prior quarter.
  • Over the last five years, EBITDA Margin for GTHP hit a ceiling of 120.34% in Q4 2025 and a floor of 53400.0% in Q4 2024.
  • Historically, EBITDA Margin has averaged 11790.73% across 5 years, with a median of 3626.14% in 2023.
  • Biggest five-year swings in EBITDA Margin: tumbled -5188438bps in 2024 and later skyrocketed 5327966bps in 2025.
  • Tracing GTHP's EBITDA Margin over 5 years: stood at 725.0% in 2021, then tumbled by -5528bps to 40800.0% in 2022, then skyrocketed by 96bps to 1515.62% in 2023, then tumbled by -3423bps to 53400.0% in 2024, then surged by 100bps to 120.34% in 2025.
  • Business Quant data shows EBITDA Margin for GTHP at 120.34% in Q4 2025, 808.33% in Q3 2025, and 652.14% in Q2 2025.